KemPharm uses its LAT™ platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

Based on this approach, we have created a portfolio of product candidates that we believe will offer significant improvements over FDA-approved and widely prescribed drugs.


Selected KemPharm Prodrug Product Candidates  

Product Candidate Parent Drug Development Status Next Milestone Potential NDA Submission


KP415 Methylphenidate (ER) Clinical PK + Efficacy Data 2018
KP484 Methylphenidate (ER) Clinical PK + Efficacy Data 2019


Apadaz Hydrocodone/APAP NDA Resbumitted PDUFA (Feb. 23, 2018) Completed
KP201/IR Hydrocodone Clinical IN HAL Data 2018 with Priority Review
KP511/ER Hydromorphone Clinical POC in ER Formulation 2019 with Priority Review
KP511/IR Hydromorphone Clinical HAL + BE Data 2019 with Priority Review
KP606/IR Oxycodone Preclinical Preclinical Development TBD
KP746 Oxymorphone Preclinical Preclinical Development TBD

Multiple CNS Disorders

KP303 Quetiapine Preclinical Preclinical Development TBD